Allena Pharmaceuticals, Inc. Operating Cash Flow Margin

Operating Cash Flow Margin of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Cash Flow Margin growth rates and interactive chart.


Highlights and Quick Summary

  • Operating Cash Flow Margin for the quarter ending March 31, 2022 was 0.0% (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Operating Cash Flow Margin decreased by NaN%
  • Annual Operating Cash Flow Margin for 2021 was 0.0% (a NaN% decrease from previous year)
  • Annual Operating Cash Flow Margin for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual Operating Cash Flow Margin for 2019 was 0.0% (a NaN% decrease from previous year)
  • Twelve month Operating Cash Flow Margin ending March 31, 2022 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Operating Cash Flow Margin decreased by NaN% year-over-year
Trailing Operating Cash Flow Margin for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
0.0% 0.0% 0.0% 0.0%
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Cash Flow Margin of Allena Pharmaceuticals, Inc.

Most recent Operating Cash Flow Marginof ALNA including historical data for past 10 years.

Interactive Chart of Operating Cash Flow Margin of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Operating Cash Flow Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.0%
2021 0.0% 0.0% 0.0% 0.0% 0.0%
2020 0.0% 0.0% 0.0% 0.0% 0.0%
2019 0.0% 0.0% 0.0% 0.0% 0.0%
2018 0.0% 0.0% 0.0% 0.0% 0.0%
2017 0.0% 0.0% 0.0% 0.0% 0.0%
2016 0.0% 0.0% 0.0%
2015 0.0% 0.0%

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.